Scynexis (SCYX) stock jumped 10% pre-market after acquiring PXL-770, a potential treatment for polycystic kidney disease, from Poxel SA. The company also secured $40 million via a private placement to fund the acquisition. Scynexis plans to launch a Phase 2 study in late 2026 for the therapy, which has received Orphan Drug Designation.